CA2237529A1 - Vaccine compositions for intranasal administration comprising chitosan and use thereof - Google Patents

Vaccine compositions for intranasal administration comprising chitosan and use thereof

Info

Publication number
CA2237529A1
CA2237529A1 CA002237529A CA2237529A CA2237529A1 CA 2237529 A1 CA2237529 A1 CA 2237529A1 CA 002237529 A CA002237529 A CA 002237529A CA 2237529 A CA2237529 A CA 2237529A CA 2237529 A1 CA2237529 A1 CA 2237529A1
Authority
CA
Canada
Prior art keywords
chitosan
intranasal administration
vaccine compositions
compositions
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002237529A
Other languages
French (fr)
Other versions
CA2237529C (en
Inventor
Lisbeth Illum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Danbiosyst Uk Limited
Lisbeth Illum
West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited
Archimedes Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst Uk Limited, Lisbeth Illum, West Pharmaceutical Services Drug Delivery & Clinical Research Centre Limited, Archimedes Development Limited filed Critical Danbiosyst Uk Limited
Publication of CA2237529A1 publication Critical patent/CA2237529A1/en
Application granted granted Critical
Publication of CA2237529C publication Critical patent/CA2237529C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution

Abstract

There is provided vaccine compositions for intranasal administration, which compositions comprise one or more antigens and an effective adjuvant amount of a chitosan.
CA002237529A 1995-12-07 1996-12-09 Vaccine compositions for intranasal administration comprising chitosan and use thereof Expired - Fee Related CA2237529C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9525083.3A GB9525083D0 (en) 1995-12-07 1995-12-07 Vaccine compositions
GB9525083.3 1995-12-07
PCT/GB1996/003019 WO1997020576A1 (en) 1995-12-07 1996-12-09 Vaccine compositions for intranasal administration comprising chitosan and use thereof

Publications (2)

Publication Number Publication Date
CA2237529A1 true CA2237529A1 (en) 1997-06-12
CA2237529C CA2237529C (en) 2008-10-14

Family

ID=10785093

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002237529A Expired - Fee Related CA2237529C (en) 1995-12-07 1996-12-09 Vaccine compositions for intranasal administration comprising chitosan and use thereof

Country Status (13)

Country Link
US (2) US6391318B1 (en)
EP (1) EP0865297B1 (en)
JP (1) JP4063876B2 (en)
AT (1) ATE227134T1 (en)
CA (1) CA2237529C (en)
DE (1) DE69624726T2 (en)
DK (1) DK0865297T3 (en)
ES (1) ES2186809T3 (en)
GB (2) GB9525083D0 (en)
NO (1) NO323084B1 (en)
NZ (1) NZ323973A (en)
PT (1) PT865297E (en)
WO (1) WO1997020576A1 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
US5993852A (en) * 1997-08-29 1999-11-30 Pharmaderm Laboratories Ltd. Biphasic lipid vesicle composition for transdermal administration of an immunogen
GB9725084D0 (en) * 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
US7022683B1 (en) * 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
JP2002540076A (en) * 1999-03-24 2002-11-26 イギリス国 Vaccine composition
GB9914412D0 (en) * 1999-06-22 1999-08-18 Worrall Eric E Method for the preservation of viruses,bacteria and biomolecules
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
US7767197B2 (en) 2000-06-22 2010-08-03 Endo Pharmaceuticals Colorado LLC Delivery vehicle composition and methods for delivering antigens and other drugs
AU2002210407A1 (en) * 2000-10-27 2002-05-06 Pharmexa A/S Therapeutic vaccine formulations containing chitosan
US6777000B2 (en) * 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US7494669B2 (en) * 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
ATE375786T1 (en) 2001-08-16 2007-11-15 Cmp Therapeutics Ltd CHITIN MICROPARTICLES AND THEIR MEDICAL USE
EP1441762A1 (en) 2001-09-28 2004-08-04 University Of South Florida Rsv gene expression vaccine
KR20040073438A (en) * 2001-11-19 2004-08-19 벡톤 디킨슨 앤드 컴퍼니 Pharmaceutical compositions in particulate form
EP1506007B1 (en) * 2002-05-14 2011-06-22 Novartis Vaccines and Diagnostics S.r.l. Mucosal combination vaccines for bacterial meningitis
MXPA04011249A (en) * 2002-05-14 2005-06-06 Chiron Srl Mucosal vaccines with chitosan adjuvant and meningococcal antigens.
GB0302218D0 (en) * 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
WO2004003145A2 (en) * 2002-06-28 2004-01-08 Nastech Pharmaceutical Company Inc. Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds
EP1594536B1 (en) * 2003-01-30 2009-03-25 Novartis Vaccines and Diagnostics, Inc. Adjuvanted influenza vaccine
JP2006516609A (en) * 2003-01-30 2006-07-06 カイロン ソチエタ ア レスポンサビリタ リミタータ Mucosal meningococcal vaccine
CA2516188C (en) 2003-02-14 2012-04-17 University Of South Florida Chitosan-derivatives for gene delivery and expression
WO2004076664A2 (en) * 2003-02-21 2004-09-10 University Of South Florida Vectors for regulating gene expression
CA2523870A1 (en) * 2003-04-30 2004-11-18 Nastech Pharmaceutical Company Inc. Claudins' underexpression as markers of tumor metastasis
US20040248804A1 (en) * 2003-05-01 2004-12-09 Khurshid Iqbal Nasal administration of the LH-RH analog Leuprolide
EP1631308B1 (en) * 2003-05-30 2013-07-31 Amylin Pharmaceuticals, LLC Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
CA2548150A1 (en) 2003-12-04 2005-06-23 University Of South Florida Polynucleotides for reducing respiratory syncytial virus gene expression
US7968122B2 (en) * 2003-12-10 2011-06-28 Adventrx Pharmaceuticals, Inc. Anti-viral pharmaceutical compositions
US20050129679A1 (en) * 2003-12-15 2005-06-16 Nastech Pharmaceutical Company Inc. Method for opening tight junctions
US7740883B2 (en) * 2004-03-28 2010-06-22 University Of Debrecen Nanoparticles from chitosan
JP2007536259A (en) * 2004-05-06 2007-12-13 イヴレア ファーマスーティカルズ インコーポレイテッド Particles for active drug delivery
US20090069226A1 (en) * 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
US20050283004A1 (en) 2004-06-18 2005-12-22 Hopax Chemicals Manufacturing Co., Ltd. Alkylsulfonated polyaminosaccharides
WO2006030730A1 (en) * 2004-09-15 2006-03-23 Otsuka Pharmaceutical Co., Ltd. Permucosal composition and method of improving permucosal absorption
WO2007086923A2 (en) * 2005-05-23 2007-08-02 University Of South Florida Controlled and sustained gene transfer mediated by thiol-modified polymers
US20080184618A1 (en) * 2005-08-03 2008-08-07 Amcol International Virus-Interacting Layered Phyllosilicates and Methods of Use
US20070031512A1 (en) * 2005-08-03 2007-02-08 Amcol International Corporation Virus-interacting layered phyllosilicates and methods of inactivating viruses
US20100272769A1 (en) * 2005-08-03 2010-10-28 Amcol International Virus-, Bacteria-, and Fungi-Interacting Layered Phyllosilicates and Methods of Use
US8536324B2 (en) * 2005-10-21 2013-09-17 University Of South Florida Method of drug delivery by carbon nanotube-chitosan nanocomplexes
EP1948810A4 (en) * 2005-11-04 2010-06-30 Biosyntech Canada Inc Composition and method for efficient delivery of nucleic acids to cells using chitosan
CA2635603C (en) 2005-11-30 2016-01-19 Endo Pharmaceuticals Inc. Treatment of xerostomia
US8846102B2 (en) * 2006-03-30 2014-09-30 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
AU2007262845B2 (en) 2006-06-20 2013-07-25 Mucovax Inc. Compositions comprising chitin microparticles and their medical uses
CA2664157C (en) 2006-09-29 2015-12-01 Ligocyte Pharmaceuticals, Inc. Norovirus vaccine formulations
EP2112923A1 (en) 2007-01-22 2009-11-04 Targacept Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
US20080182819A1 (en) * 2007-01-29 2008-07-31 Act Iii Licensing, Llc Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders
WO2008147807A2 (en) 2007-05-23 2008-12-04 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
JP2010539192A (en) 2007-09-18 2010-12-16 リゴサイト ファーマスーティカルズ，インコーポレイテッド Methods for conferring a protective immune response against norovirus
US20100266636A1 (en) * 2007-09-18 2010-10-21 Ligocyte Pharmaceuticals, Inc. Method of conferring a protective immune response to norovirus
BRPI0905725B8 (en) * 2008-01-11 2021-05-25 Univ Emory vaccine and pharmaceutical packaging
WO2009108867A1 (en) 2008-02-27 2009-09-03 Amcol International Corporation Methods of treating cardiovascular disorders associated with atherosclerosis
ES2668836T3 (en) 2008-08-08 2018-05-22 Takeda Vaccines, Inc. Similiviral particles comprising amino acid sequences of the compound capsid for enhanced cross-reactivity
WO2010119112A1 (en) * 2009-04-15 2010-10-21 Ceva Sante Animale Recombinant avian herpes virus vectors and vaccine for immunizing waterfowl species
CA2841356C (en) 2011-07-11 2022-03-01 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
ES2932952T3 (en) 2012-04-24 2023-01-30 Ohio State Innovation Foundation Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
US10279028B2 (en) 2012-04-24 2019-05-07 Ohio State Innovation Foundation Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome
CN108715607B (en) * 2018-04-12 2021-12-10 华南农业大学 Recombinant cholera toxin B subunit protein, PEDV inactivated vaccine, preparation and application
CN109172817B (en) * 2018-08-16 2021-10-26 华中农业大学 Preparation method and application of chitosan microspheres of attenuated live vaccine of porcine epidemic diarrhea virus
EP3698773A1 (en) 2019-02-21 2020-08-26 Università degli Studi di Parma Composition and manufacturing of powders containing nanoadjuvants for mucosal vaccination

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1261264A (en) * 1984-11-29 1989-09-26 Shigeo Suzuki Immunopotentiating agents and method
US4950740A (en) * 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
US5554388A (en) * 1989-02-25 1996-09-10 Danbiosyst Uk Limited Systemic drug delivery compositions comprising a polycationi substance
GB8904370D0 (en) * 1989-02-25 1989-04-12 Cosmas Damian Ltd Liquid delivery compositions
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
US5912000A (en) * 1994-09-23 1999-06-15 Zonagen, Inc. Chitosan induced immunopotentiation
WO1996009805A2 (en) 1994-09-23 1996-04-04 Zonagen, Inc. Chitosan induced immunopotentiation
GB9419979D0 (en) 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
JP2001523216A (en) * 1995-06-26 2001-11-20 リサーチ．トライアングル．ファーマシューティカルズ Novel adjuvant composition and vaccine formulation comprising the same
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions

Also Published As

Publication number Publication date
GB9811810D0 (en) 1998-07-29
ES2186809T3 (en) 2003-05-16
NZ323973A (en) 2004-12-24
US7323183B2 (en) 2008-01-29
DK0865297T3 (en) 2003-03-03
GB2322801A (en) 1998-09-09
GB9525083D0 (en) 1996-02-07
ATE227134T1 (en) 2002-11-15
AU705452B2 (en) 1999-05-20
JP2000501412A (en) 2000-02-08
JP4063876B2 (en) 2008-03-19
PT865297E (en) 2003-03-31
WO1997020576A1 (en) 1997-06-12
DE69624726T2 (en) 2003-09-18
GB2322801B (en) 2000-01-19
US6391318B1 (en) 2002-05-21
EP0865297A1 (en) 1998-09-23
CA2237529C (en) 2008-10-14
NO982497L (en) 1998-06-02
US20030039665A1 (en) 2003-02-27
NO982497D0 (en) 1998-06-02
AU1102597A (en) 1997-06-27
EP0865297B1 (en) 2002-11-06
DE69624726D1 (en) 2002-12-12
NO323084B1 (en) 2006-12-27

Similar Documents

Publication Publication Date Title
CA2237529A1 (en) Vaccine compositions for intranasal administration comprising chitosan and use thereof
CA2217178A1 (en) Vaccines containing a saponin and a sterol
AU1308495A (en) Influenza vaccine
CA2177668A1 (en) Mammalian vaccine compositions comprising squalene or squalane, glycerol and a surfactant as an adjuvant
CA2218714A1 (en) Dosage form comprising oxybutynin
GB9725084D0 (en) Vaccine compositions
IL117249A0 (en) Vaccine compositions
AU4370396A (en) Gram negative bacterial infection vaccine
AU678971B2 (en) Compositions and methods for vaccination against coronaviruses
AU699020B2 (en) Liquid formulations of 1,2-benzisothiazolin-3-one
CA2177667A1 (en) Mammalian vaccine compositions comprising squalene or squalane, lecithin and a polyoxyethylene sorbitan ester as an adjuvant
AU3125795A (en) Attenuated human rotavirus vaccine
EP0745648A3 (en) Stable dispersible silicone compositions
AU3154395A (en) Contraceptive vaccine
CA2215520A1 (en) Chlamydia vaccines
AU2769595A (en) Contraceptive vaccine
AU5168496A (en) Butyryl-tyrosinyl spermine, analogs thereof and methods of preparing and using same
AU4450696A (en) Enhanced immunogenic vaccine
AU1164597A (en) Ifosfamide, analogues thereof and their preparation
AU5240896A (en) Marek's disease vaccine
AU1194997A (en) Plasmid vaccine against pseudorabies virus
CA2176929A1 (en) Vaccine against mumps containing a jeryl-lynn virus strain
AU7728596A (en) Isolation of apo(a), compositions, and methods of use
AU5100696A (en) Specific hiv-1 group o antigens
AU1825895A (en) Retroviral vaccines, vaccination and immune-therapy for retroviral infections

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20161209